Response to PD1 inhibition in conventional chondrosarcoma

Area of Science:

• Oncology
• Immunotherapy
• Bone Tumors

Background:

• Conventional chondrosarcoma is a common adult bone malignancy.
• It is often resistant to traditional chemotherapy treatments.
• Metastatic disease presents significant treatment challenges.

Observation:

• A 67-year-old male with metastatic conventional chondrosarcoma received nivolumab.
• Initial restaging indicated increased tumor burden, leading to treatment discontinuation.
• This apparent progression was later identified as pseudoprogression.

Findings:

• The patient restarted nivolumab after the pseudoprogression diagnosis.
• He subsequently achieved a near-complete response to the immunotherapy.
• Conventional chondrosarcoma demonstrated sensitivity to checkpoint inhibitors.

Implications:

• Pseudoprogression is a critical factor in assessing treatment response for chondrosarcoma.
• Checkpoint inhibitors like nivolumab show potential in treating this deadly bone cancer.
• Further research into immunomodulatory agents for chondrosarcoma is warranted.